The system is based on the Yellow Card Scheme and is designed to make completing a report quick and easy for healthcare professionals and the public.
This will assist the MHRA in efficiently monitoring the safety of the swine flu antiviral medicines, Tamiflu and Relenza, as their use increases during the swine flu pandemic.
Dr June Raine, director of vigilance and risk management of medicine at the MHRA, said: ‘Tamiflu and Relenza are acceptably safe and most people will not suffer any side effects.
‘Like all medicines, the MHRA keeps the safety of these continually under review and we are keen to let people know there is a new way to tell us of any side effect suspicions.’
VISIT OUR SWINE FLU RESOURCE CENTRE
More news from 7 July